Get FREE U.S. Shipping on $75 Orders*

Single-blind, placebo phase-in trial of 2 escalating doses of selegiline in the Chronic Fatigue Syndrome (CFS)

1 Star2 Stars3 Stars4 Stars5 Stars ((68) votes, average 2.95 out of 5)

AIM: To perform a clinical trial of selegiline in 25 patients

with chronic fatigue syndrome (CFS) where patients were told

they would receive placebo or active agent at different times

during the 6-week trial. We chose selegiline, a specific

monoamine oxidase (MAO) B receptor inhibitor, because a prior

trial of lowdose phenelzine, a nonspecific MAO inhibitor,

showed a small but significant therapeutic effect.


Questionnaires comprised of 19 tests of mood, fatigue,

functional status and symptom severity were collected at the

start and end of the trial as well as 2 weeks after its start.

The trial was done in three 2-week blocks: in the first, 2

placebo pills were given per day; in the next, one 5-mg tablet

of agent and one placebo were given per day, and in the last,

a 5-mg tablet of agent was given twice a day. The plan was to

compare the changes in the 19 tests during the placebo phase

to those found in the active treatment phase in 19 patients

completing the trial.

FINDINGS: Significant improvement in 3

variables- tension/anxiety, vigor and sexual relations-was

found. A significant pattern of improvement compared to

worsening was found for the 19 self- report vehicles during

active treatment as compared with placebo treatment. Evidence

for an antidepressant effect of the drug was not found.

CONCLUSIONS: Selegiline has a small but significant

therapeutic effect in CFS which appears independent of an

antidepressant effect.

share this article

share your comments

Enrich and inform our Community. Your opinion matters!

Leave a Reply

Your email address will not be published. Required fields are marked *

ProHealth CBD Store